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Abstract
Introduction A genetic component is well established in the
etiology of breast cancer. It is not well known, however, whether
genetic traits also influence prognostic features of the malignant
phenotype.
Methods We carried out a population-based cohort study in
Sweden based on the nationwide Multi-Generation Register.
Among all women with breast cancer diagnosed from 1961 to
2001, 2,787 mother-daughter pairs and 831 sister pairs with
breast cancer were identified; we achieved complete follow-up
and classified 5-year breast cancer-specific prognosis among
proband (mother or oldest sister) into tertiles as poor,
intermediary, or good. We used Kaplan-Meier estimates of
survival proportions and Cox models to calculate relative risks of
dying from breast cancer within 5 years depending on the
proband's outcome.
Results The 5-year survival proportion among daughters whose
mothers died within 5 years was 87% compared to 91% if the
mother was alive (p = 0.03). Among sisters, the corresponding
proportions were 70% and 88%, respectively (p = 0.001). After
adjustment for potential confounders, daughters and sisters of a
proband with poor prognosis had a 60% higher 5-year breast
cancer mortality compared to those of a proband with good
prognosis (hazard ratio [HR], 1.6; 95% confidence interval [CI],
1.2 to 2.2; p  for trend 0.002). This association was slightly
stronger among sisters (HR, 1.8; 95% CI, 1.0 to 3.4) than
among daughters (HR, 1.6; 95% CI, 1.1 to 2.3).
Conclusion Breast cancer prognosis of a woman predicts the
survival in her first-degree relatives with breast cancer. Our
novel findings suggest that breast cancer prognosis might be
inherited.
Introduction
Breast cancer, the most common female malignancy, has an
important genetic contribution estimated to 25% to 28%
[1,2]. Mutations in high-penetrant genes such as BRCA1
(breast cancer 1, early onset) and BRCA2 account for only a
small proportion of this hereditary component, suggesting an
important but yet-to-be-detected role for low-penetrant single
nucleotide polymorphisms. Overall, the prognosis of women
with a family history of breast cancer has been reported as
similar or worse compared to women without a family history
[3-6]. A relatively poor outcome has been reported among
BRCA1-positive women [6], but some controversy still
remains [7]. There is also evidence that some non-genetic risk
factors such as hormone replacement therapy (HRT) and
obesity influence both the incidence [8-10] and the prognosis
[11-13] of breast cancer.
We hypothesized that genetic traits may influence not only the
risk of developing breast cancer but also prognostically impor-
tant features of the malignant phenotype. To the best of our
knowledge, this hypothesis has never been adequately inves-
tigated. To this end, we identified women with incident breast
cancer and analyzed breast cancer prognosis among 2,787
mother-daughter pairs and 831 sister pairs, all of whom had
breast cancer diagnosed in Sweden from 1961 to 2001. We
achieved complete follow-up and unbiased information on
family history through record linkages.
Materials and methods
Study cohort
The Multi-Generation Register includes all Swedish residents
born after 1931, who were alive in 1960, and all those born
thereafter. It contains links between children and parents
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through their national registration numbers, which are
assigned to all residents of Sweden. From 1961 to 2001, the
completeness of the Multi-Generation Register became pro-
gressively better, and from 1991 it is considered to be com-
plete [14]. Therefore, among individuals who died before
1991, notification of their mothers in the Multi-Generation
Register has some degree of incompleteness. Information on
cancer was obtained from the nationwide Swedish Cancer
Registry, established in 1958. For the period of our study
(1961 to 2001), the cancer registry was estimated to be at
least 98% complete [15]. For each notified cancer, the cancer
registry records the national registration number, International
Classification of Diseases code, date of diagnosis, and area of
residence at diagnosis. Information on stage of disease and
treatment is not included in the registry.
Further record linkages to the nationwide Cause of Death
Register and the Total Population Register allowed complete
follow-up with regard to vital status, date and underlying
causes of death, as well as dates of emigration and immigra-
tion. Follow-up started in 1961 because the Cause of Death
Register has a high reported accuracy (96%) [16] from that
year onward. Finally, additional linkages were made to the cen-
suses of 1960, 1970, 1980, and 1990, which contain informa-
tion on the socioeconomic status of each Swedish citizen.
From a total population cohort of about 11 million individuals
recorded in the Multi-Generation Register, we identified
36,554 female offspring who were born in Sweden since
1932 and who had a first primary invasive breast cancer diag-
nosed from 1961 to 2001. Subsequently, we identified all
mothers and sisters of these women who were also born in
Sweden and whose first primary invasive breast cancer was
diagnosed during the same period. We excluded all women for
whom the history of breast cancer was uncertain because they
had immigrated to Sweden and all women with any primary
malignant tumor other than a breast cancer prior to the first
breast cancer. Our final dataset comprised a total of 2,787
mother-daughter pairs and 831 sister pairs with incident
breast cancer.
Parity and age at first birth were extracted from information on
offspring available in the Multi-Generation Register. Area of
residence at diagnosis was obtained from the Cancer Registry
and categorized into the six health care regions in Sweden.
Socioeconomic status, estimated from the highest level of
employment in the household reported in the censuses, was
categorized into four groups: self-employed, blue-collar
worker, and low-level and high-level white-collar worker.
Statistical methods
All analyses are based on breast cancer-specific mortality
among patients with an affected mother or sister (proband).
We limited the outcome estimate to 5 years because it is a
clinically accepted estimate of prognosis. The person-time at
risk started at the date of first diagnosis of breast cancer and
continued until emigration, end of follow-up (31 December
2001), or death, whichever came first. In the sister pair analy-
sis, the older sister was chosen as the proband for reasons of
better statistical power by an approximately equal number of
deaths between the sister pairs. All of the data preparation and
analysis were carried out using the SAS Statistical package,
version 8.2 (SAS Institute Inc., Cary, NC, USA) [17].
Firstly, we conducted a univariable analysis crudely grouping
the proband (mother or sister) into either dead due to breast
cancer within 5 years of diagnosis or alive 5 years after diag-
nosis. Due to the end of follow-up of the register in December
2001, we restricted the date of diagnosis until 1996 to ensure
that all probands had the possibility of 5-year survival. We
used the Kaplan-Meier method to estimate survival propor-
tions, looking at differences in cause-specific death depend-
ing on the proband's prognosis. To increase validity and to
avoid confounding by period, we restricted follow-up for the
daughters and sisters at risk to the years since 1991.
Secondly, our ultimate aim was to model the prognosis of the
daughters and sisters as a function of the prognosis of the
proband (mother or older sister, respectively). We first needed
to classify the prognosis of the proband, and we did so based
on the deviance residual from a multivariable proportional haz-
ards (Cox) model fitted to the proband data adjusting for
period and age of diagnosis. The deviance residual provides a
measure of how the survival of the proband compares to other
probands with the same age and year of diagnosis. Because
the residual is calculated as observed minus expected mortal-
ity, values below, above, and around zero correspond to prog-
noses of better, worse, or as expected, respectively. The
deviance residuals are more symmetrically distributed about
zero than the unadjusted (crude) residuals. We defined the
good prognosis group as the first tertile of the deviance resid-
ual distribution, the medium prognosis group as the second
tertile, and the poor prognosis group as the third tertile. Finally,
the association between the cause-specific hazard in the
prognoses of daughters or sisters and probands was investi-
gated employing a proportional hazards model adjusting for all
available confounders such as age and calendar period of
diagnosis, parity, age at first birth, socioeconomic factors, and
area of residence at diagnosis.
Finally, due to limited statistical power to model the effect of
age, we instead examined the concordance proportion in
prognosis between mother-daughter pairs by using the mod-
eled estimates of prognosis. We examined the relationship
between the age of the mother at diagnosis and the
concordance in prognosis (good, medium, or poor) and
assessed the trend in relation to age.Available online http://breast-cancer-research.com/content/9/3/R39
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Results
Univariable analysis
Table 1 presents patient characteristics of the breast cancer
pairs. Mothers with breast cancer had a widely distributed
range of age at diagnosis and period of diagnosis. In contrast,
daughters and sisters with breast cancer were limited in age
to less than 70 years and their tumors were diagnosed pre-
dominantly at the end of the study period. Information on parity
and age at first birth is used to describe the risk of death in the
daughters or younger sisters only.
We categorized the proband into categories of vital status 5
years after diagnosis and studied the 5-year survival propor-
tion in their daughters or sisters. We present Kaplan-Meier
plots of patients with recently diagnosed (since 1991) breast
cancer (Figure 1). The 5-year cause-specific survival
proportion for daughters whose cancer was diagnosed since
1991 and whose mothers died within 5 years was 87% (95%
confidence interval [CI], 82% to 91%) compared to 91%
(95% CI, 89% to 93%) for daughters whose proband was
alive after 5 years (log rank test, p = 0.03) (Figure 1a).
Mothers are older and their tumors were diagnosed in earlier
calendar periods, making a comparison to sisters difficult. To
compare mother-daughter pairs to sister pairs, we limited the
age of the mother at diagnosis to that of the sister (that is, age
of less than 70 years at diagnosis) (Figure 1b). The 5-year
cause-specific survival proportion for daughters whose cancer
was diagnosed since 1991 and whose mothers were younger
than 70 years at diagnosis and died within 5 years was 83%
(95% CI, 75% to 89%) compared to 90% (95% CI, 87% to
93%) for daughters whose proband was alive after 5 years
(log rank test, p = 0.01). Finally, the 5-year cause-specific sur-
vival proportion for a woman whose older sister died of the dis-
ease within 5 years was 70% (95% CI, 46% to 85%)
compared to 88% (95% CI, 82% to 92%) for sisters whose
proband was alive after 5 years (log rank test, p = 0.01) (Fig-
ure 1c).
Table 1
Characteristics of 2,787 mother-daughter pairs and 831 sister pairs with primary breast cancer in Sweden from 1961 to 2001
Mother Daughter Older sister Younger sister
Number Percentage Number Percentage Number Percentage Number Percentage
Number 2,787 2,787 831 831
Overall deaths 2,010 72.1 511 18.3 182 21.9 148 17.8
Cause-specific deaths 1,009 36.2 395 14.2 133 15.9 120 14.4
Age at diagnosis (years)
<40 56 1.9 417 14.4 63 7.6 117 14.1
40–49 305 10.6 1,148 39.8 264 31.8 346 41.6
50–59 560 19.4 1,033 35.8 354 42.6 313 37.7
60–69 826 28.6 288 10.0 150 18.0 55 6.6
70+ 1,139 39.5 0 - 0 - 0 -
Median age at diagnosis (years) 66 49 49 48
Year of diagnosis
1961–1969 443 15.9 9 0.3 2 0.2 0 -
1970–1979 714 25.6 88 3.2 49 5.9 27 3.3
1980–1989 852 30.6 601 21.6 222 26.7 160 19.2
1990- 778 27.9 2,089 74.9 558 67.2 644 77.5
Parity
Nulliparous/missing 421 15.1 107 12.9
1 493 17.7 124 14.9
2 1,221 43.8 381 45.9
3+ 652 23.4 219 26.3
Median age at first birth (years) 25 24Breast Cancer Research    Vol 9 No 3    Hartman et al.
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Multivariable analyses
Using a Cox proportional hazards model, we present the 5-
year breast cancer-specific mortality for daughters and sisters
by proband's prognosis (good, medium, or poor) (Table 2).
We estimated the 5-year cause-specific mortality of the breast
cancer patients by mother or sister proband separately. We
present two separate models for all pairs, one with adjustment
for age at and calendar period of diagnosis, another with addi-
tional adjustment for age at first birth, parity, socioeconomic
status, and area of residence. The multivariable risk to die from
breast cancer in the final model was 60% higher in daughters
(hazard ratio [HR] 1.6; 95% CI, 1.1 to 2.3) and 80% higher in
sisters (HR 1.8; 95% CI, 1.0 to 3.4) of a proband with poor
prognosis as compared to those of a proband with good prog-
nosis. Analyzing sisters and daughters together resulted in a
similarly increased risk to die from breast cancer (Table 2). To
achieve comparable age range in mothers and daughters, we
analyzed only pairs with mothers younger than 70 years at
diagnosis. Results were similar to the unrestricted analysis
(data not shown).
As a validation analysis, we restricted our analysis to include
only all patients with breast cancer (daughters and sisters)
diagnosed since 1991 (n = 2,590), a period with complete
family links. The 5-year cause-specific mortality of the patients
with breast cancer in the final fully adjusted model was 90%
higher in women (HR 1.9; 95% CI, 1.3 to 2.8; n = 73) whose
proband had poor prognosis and 70% higher (HR 1.7; 95%
CI, 1.1 to 2.5; n = 73) if the proband had medium prognosis
compared to women whose proband had good prognosis (n
= 40; p  for trend = 0.002). Because the findings are in
agreement with the whole period analysis, the results are in
support of a high internal validity.
We analyzed the importance of age at diagnosis by calculating
the concordance proportion of prognosis within mother-
daughter pairs (Table 3). The overall concordance in progno-
sis (good, medium, or poor) between mother-daughter pairs
was strongest among pairs with mothers whose cancer was
diagnosed at less than 40 years of age (p for trend <0.001).
When analyzing the poor prognosis concordance, the trend by
age was equally significant.
Discussion
Our results suggest that the prognosis of breast cancer has an
inherited component. The survival of women with familial
breast cancer is indeed predicted by the prognosis of her first-
degree relative with breast cancer. Contrasting women with
relatives of really good prognosis to those of poor prognosis
showed a 60% to 80% higher mortality rate among first-
degree relatives of women with a relative with poor prognosis.
The concordance in prognosis was more pronounced in
women with first-degree family members whose cancer was
diagnosed at a young age.
Figure 1
Kaplan-Meier estimates of breast cancer-specific mortality of women  whose cancer was diagnosed since 1991 and who have a first-degree  relative with breast cancer Kaplan-Meier estimates of breast cancer-specific mortality of women 
whose cancer was diagnosed since 1991 and who have a first-degree 
relative with breast cancer. Estimates are stratified by proband's cause-
specific outcome. (a) One thousand seven hundred seventy-eight 
daughters with mother as proband. (b) Eight hundred forty-nine daugh-
ters with a mother younger than 70 years of age as proband. (c) Three 
hundred forty-eight sisters with an older sister as proband.Available online http://breast-cancer-research.com/content/9/3/R39
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Strengths of our study include the large size, the population-
based prospective design, the unbiased definition of family
history and outcome, as well as the completeness of follow-up.
A complicated issue is whether the lack of information of clin-
ical covariates (such as stage of disease, hormone receptor
status, histopathologic features, and ploidy) limits the validity
of our findings. We argue that adjusting for such factors in the
analysis is inappropriate. If familial clustering of prognosis
reflects a genuine biologic phenomenon, it would be mirrored
in established prognostic factors. Indeed, if we could measure
the biologic aggressiveness of the tumor precisely, adjustment
would eliminate the association completely. Still, information
on clinical covariates and, in the best possible scenario, infor-
mation on BRCA1, BRCA2, and CHEK2 (CHK2 checkpoint
homolog [Schizosaccharomyces pombe]) might have allowed
a deeper understanding of the biologic mechanisms by which
prognostic outcome is determined by breast cancer survival
among previously affected relatives. Confounding by subopti-
mal treatment within some families is a more serious concern
discussed below.
Before we accept familial clustering of breast cancer progno-
sis as a genuine biologic phenomenon, several rival interpreta-
tions need consideration. Unavoidably, some time normally
lapses between detectability – typically through self-examina-
tion – and clinical diagnosis followed by treatment of breast
cancer. This delay is likely affected by factors such as aware-
ness, denial, socioeconomic status, and access to health care.
Though these factors are likely to be correlated among first-
degree relatives, several circumstances argue against these
factors as major contributors to our findings. Our estimates on
inheritance of prognosis in the adjusted model, including soci-
oeconomic status and area of residence, are robust (Table 2).
Furthermore, self-examination has never been documented to
measurably reduce breast cancer mortality [18] and Sweden
has a public health care system available to everyone at mini-
mal cost. Hence, difference in access to health care is an
unlikely explanation to major differences in breast cancer prog-
nosis between families. Finally, awareness of breast cancer
might be higher among first-degree relatives of a woman who
died rather than among relatives of someone who was cured
Table 2
Survival model of the cause-specific mortality of women with primary breast cancer by prognosis in probanda
Deaths Adjustedb Adjustedc
HR (95% CI) HR (95% CI)
2,787 Mother-daughter pairs
Proband prognosisd
Poor (tertile 1: <33%) 84 1.6 (1.1–2.3) 1.6 (1.1–2.3)
Medium (tertile 2: 33%–66%) 83 1.4 (1.0–2.0) 1.4 (1.0–2.0)
Good (tertile 3: >67%) 53 1.0 reference 1.0 reference
Test for trend p = 0.007 p = 0.006
831 Sister pairs
Proband prognosisd
Poor (tertile 1: <33%) 26 1.7 (0.9–3.2) 1.8 (1.0–3.4)
Medium (tertile 2: 33%–66%) 23 1.4 (0.7–2.6) 1.5 (0.8–2.9)
Good (tertile 3: >67%) 17 1.0 reference 1.0 reference
Test for trend p = 0.08 p = 0.06
Combined (daughter and sister)
Proband prognosisd
Poor (tertile 1: <33%) 110 1.6 (1.2–2.2) 1.6 (1.2–2.2)
Medium (tertile 2: 33%–66%) 106 1.4 (1.0–1.9) 1.4 (1.1–1.9)
Good (tertile 3: >67%) 70 1.0 reference 1.0 reference
Test for trend p = 0.002 p = 0.002
aCox proportional hazards model of the 5-year cause-specific mortality of 3,618 women with primary breast cancer by prognosis in proband 
(mother or older sister). bAdjusted for age and period of diagnosis of the daughter or younger sister. cAdjusted for age and period of diagnosis, 
parity, age at first birth, socioeconomic status, and area of residence of the daughter or younger sister. dProband's 5-year cause-specific 
prognosis as defined by separated Cox proportional hazards model adjusted for proband's age and period of diagnosis. CI, confidence interval; 
HR, hazard ratio.Breast Cancer Research    Vol 9 No 3    Hartman et al.
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of breast cancer. If anything, such awareness should produce
results opposite to those we found [19,20].
Secondly, familial clustering in the use of mammography
screening might contribute to the pattern of results that we
found. Again, several arguments make this explanation less
likely. During the late 1980s and 1990s, service screening
with mammography first became widely available to all Swed-
ish women in relevant ages. Furthermore, the mortality differ-
ence we observed between families is substantially larger than
the documented benefit from regular mammography screen-
ing, notably among women younger than 50 years of age [16].
It is true that breast density, which affects mammographic sen-
sitivity [21,22], has a strong hereditary component [23,24].
Though unlikely as a main contributor to our findings, this issue
deserves further investigation.
A third conceivable confounding factor in our data is access to
and compliance with optimal treatment. As already empha-
sized, equality of health care is widely perceived as excellent
in Sweden and social gradients in breast cancer survival are
much smaller than the associations we found among relatives
[25]. Finally, obesity has been shown to affect breast cancer
prognosis [13]. A correlation in body weight among family
members may have affected our findings but would have been
unlikely to substantially affect our results [20]. Another factor
that has been associated with both risk and prognosis is HRT
[26,27], but correlation in HRT use across generations is not
expected to be substantial.
Our reasoning leads us to consider familial clustering of breast
cancer prognosis as a possible biologic phenomenon rather
than a consequence of confounding by factors such as aware-
ness, screening behavior, or treatment. Theoretically, such
clustering might arise as a consequence of several
mechanisms. According to our main hypothesis, germline
genetic variation may be relevant not only for risk of transfor-
mation and cancer incidence, but also for prognostically
important features of the malignant phenotype. Whereas most
studies confirm a poor prognostic outlook among BRCA1
mutation carriers [6,28], some studies present conflicting
results with regard to a poor prognosis in women with high-
penetrant mutations [7]. Additionally, little is presently known
about the possible impact of low-penetrant genetic alterations
that will constitute the majority of the genetic variation in famil-
ial breast cancer [29]. Hence, this area deserves further scien-
tific inquiry.
Another, more speculative, possibility is familial differences in
the ability to tolerate and/or respond to systemic treatment
[30]. Although low tolerance seems less likely for hormonal
manipulation (notably for treatment with antiestrogens, which
has limited side effects), it might be more relevant for chemo-
therapy [31,32]. Because systemic chemotherapy impacts
cure rates only in an adjuvant setting [31], we would expect
effects to be confined to younger women in recent decades,
when such treatment became standard among premenopau-
sal patients. However, the familial component of prognosis
was not confined to any age group or time period.
The inheritance of breast cancer prognosis has been studied
both in animal models of mammary cancer and in genetic asso-
ciation studies [33,34]. Results from mouse models suggest
that strain background is a significant determinant of experi-
mental mammary carcinoma behavior [34-36]. However, the
question of whether germline variation in human tumor sup-
pressor genes or oncogenes affects breast cancer progres-
sion is still unanswered [34]. Several investigators have
explored the possible relationship between breast cancer sur-
vival and genetic polymorphisms in growth factor receptors as
well as genes involved in angiogenesis, xenobiotic metabo-
lism, DNA repair, and the cell cycle checkpoints. Many studies
were based on small sample size, and to our knowledge, few
of the observed associations have been confirmed. One of the
largest studies to date assessed the association of polymor-
phisms in 22 DNA repair, hormone metabolism, carcinogen
Table 3
Concordance in 5-year breast cancer-specific prognosis (good, medium, or poor) among 2,787 mother-daughter pairsa
Age of mother at diagnosis (years) Concordance in poor prognosis Overall concordance in prognosis
Events Proportion Events Proportion
<40 12/13 0.92 37/43 0.86
40–49 60/66 0.91 166/264 0.62
50–59 129/147 0.88 337/522 0.64
60–69 211/251 0.84 502/819 0.61
70+ 324/442 0.73 613/1,139 0.53
All ages 736/919 0.80 1,656/2,787 0.59
Test for trend p < 0.001 p < 0.001
aConcordance in 5-year breast cancer-specific prognosis (good, medium, or poor) by age at diagnosis in mother among mother-daughter pairs as 
defined by Cox proportional hazards models.Available online http://breast-cancer-research.com/content/9/3/R39
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metabolism, and other genes with breast cancer survival in a
population-based study [37]. The authors observed the larg-
est effect on decreased survival for a gene involved in DNA
double-strand break repair, LIG4 (ligase IV). A recently pub-
lished study has demonstrated that metastatic efficiency is
modulated by the GTPase-activating protein encoded by
Sipa1 (signal-induced proliferation-associated gene 1) [38].
Conclusion
We conclude that information about the outcome of breast
cancer among affected first-degree relatives conveys prog-
nostic information relevant to women with newly diagnosed
breast cancer. This novel observation might become relevant
for clinical management provided that the post-prognostic
information can be shown to be independent of that from
established predictors of outcome. Further research into the
likely genetic determinants of inherited breast cancer progno-
sis might also provide new biologic insight. Similar studies of
other cancer sites should also be a high priority.
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